Human Recombinant Growth Factors and Their Effect on Vaginal Microbiota Modulation in Menopause Patients

INTRODUCTION Genitourinary syndrome of menopause (GSM) is a normal consequence of aging, hormonal deprivation, or cancer treatments, it is estimated to affect approximately 1 out of 2 women [1]. The most frequent symptoms are related to vaginal dryness and dyspareunia. Traditional treatments such as vaginal moisturizers may be of limited benefit, and relief of symptoms can be inconsistent or limited as well due to hyperosmotic properties of most compounds available on the market [2]. Genital and urological complications such as urinary infections and vaginitis are related to alkaline pH, leading to the replacement of normal, healthy vaginal microbiota by pathogenic anaerobic bacteria [3]. The ovulatory cycle also influences vaginal microbiota, affected by the action of estrogen and progesterone on the vaginal epithelium, due to an increase in thickness and glycogen production.